Top

Published in:

Open Access 01-06-2019 | Oncology

Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging

Authors: Edward William Johnston, Arash Latifoltojar, Harbir Singh Sidhu, Navin Ramachandran, Magdalena Sokolska, Alan Bainbridge, Caroline Moore, Hashim Uddin Ahmed, Shonit Punwani

Published in: European Radiology | Issue 6/2019

Abstract

Objectives

To determine the diagnostic accuracy and interobserver concordance of whole-body (WB)-MRI, vs. ^99mTc bone scintigraphy (BS) and ¹⁸fluoro-ethyl-choline (¹⁸F-choline) PET/CT for the primary staging of intermediate/high-risk prostate cancer.

Methods

An institutional review board approved prospective cohort study carried out between July 2012 and November 2015, whereby 56 men prospectively underwent 3.0-T multiparametric (mp)-WB-MRI in addition to BS (all patients) ± ¹⁸F-choline PET/CT (33 patients). MRI comprised pre- and post-contrast modified Dixon (mDixon), T2-weighted (T2W) imaging, and diffusion-weighted imaging (DWI). Patients underwent follow-up mp-WB-MRI at 1 year to derive the reference standard. WB-MRIs were reviewed by two radiologists applying a 6-point scale and a locked sequential read (LSR) paradigm for the suspicion of nodal (N) and metastatic disease (M1a and M1b).

Results

The mean sensitivity/specificity of WB-MRI for N1 disease was 1.00/0.96 respectively, compared with 1.00/0.82 for ¹⁸F-choline PET/CT. The mean sensitivity and specificity of WB-MRI, ¹⁸F-choline PET/CT, and BS were 0.90/0.88, 0.80/0.92, and 0.60/1.00 for M1b disease. ROC-AUC did not show statistically significant improvement for each component of the LSR; mean ROC-AUC 0.92, 0.94, and 0.93 (p < 0.05) for mDixon + DWI, + T2WI, and + contrast respectively. WB-MRI had an interobserver concordance (κ) of 0.79, 0.68, and 0.58 for N1, M1a, and M1b diseases respectively.

Conclusions

WB-MRI provides high levels of diagnostic accuracy for both nodal and metastatic bone disease, with higher levels of sensitivity than BS for metastatic disease, and similar performance to ¹⁸F-choline PET/CT. T2 and post-contrast mDixon had no significant additive value above a protocol comprising mDixon and DWI alone.

Key Points

• A whole-body MRI protocol comprising unenhanced mDixon and diffusion-weighted imaging provides high levels of diagnostic accuracy for the primary staging of intermediate- and high-risk prostate cancer.

• The diagnostic accuracy of whole-body MRI is much higher than that of bone scintigraphy, as currently recommended for clinical use.

• Staging using WB-MRI, rather than bone scintigraphy, could result in better patient stratification and treatment delivery than is currently provided to patients worldwide.

Available only for authorised users

Buyyounouski MK, Choyke PL, McKenney JK et al (2017) Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:245–253. https://doi.org/10.3322/caac.21391 CrossRefPubMedPubMedCentral

Bjurlin MA, Rosenkrantz AB, Beltran LS, Raad RA, Taneja SS (2015) Imaging and evaluation of patients with high-risk prostate cancer. Nat Rev Urol 12:617–628. https://doi.org/10.1038/nrurol.2015.242

Hövels AM, Heesakkers RA, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395

Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 43:1503–1513

Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63:1040–1048

Kapoor V, McCook BM, Torok FS (2004) An introduction to PET-CT imaging. RadioGraphics 24:523–543. https://doi.org/10.1148/rg.242025724

Linton KD, Catto JW (2012) Whole-body magnetic resonance imaging and prostate cancer metastases: a new gold standard of detection, but does it help us and at what cost? Eur Urol 62:76–77CrossRefPubMed

Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75CrossRefPubMed

Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC, Simoni P (2010) Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa). Eur Radiol 20:2973–2982

10.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H (2012) Whole-body diffusion-weighted MRI compared with 18F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 199:1114–1120

11.

Venkitaraman R, Cook GJ, Dearnaley DP et al (2009) Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 53:241–247

12.

Pasoglou V, Larbi A, Collette L et al (2014) One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified “all-in-one” imaging approach? Prostate 74:469–477CrossRefPubMed

13.

Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937CrossRefPubMed

14.

Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML (2008) Mayo Clinic validation of the D’Amico risk group classification for predicting survival following radical prostatectomy. J Urol 179:1354–1361

15.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed

16.

Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36CrossRefPubMed

17.

Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32–35CrossRefPubMed

18.

Padhani AR, Gogbashian A (2011) Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging 11(Spec No A):S129–S145. https://doi.org/10.1102/1470-7330.2011.9034

19.

Pinaquy JB, De Clermont-Galleran H, Pasticier G et al (2015) Comparative effectiveness of [(18)F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate 75:323–331

20.

Thoeny HC, Froehlich JM, Triantafyllou M et al (2014) Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology 273:125–135CrossRefPubMed

21.

Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125CrossRefPubMedPubMedCentral

22.

Van den Bergh L, Lerut E, Haustermans K et al (2015) Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol 33:109.e23–109.e31

23.

Bubendorf L, Schöpfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583CrossRefPubMed

24.

Haubold-Reuter BG1, Duewell S, Schilcher BR, Marincek B, von Schulthess GK (1993) The value of bone scintigraphy, bone marrow scintigraphy and fast spinecho magneticresonance imaging in staging of patients with malignant solid tumours: a prospectivestudy. Eur J Nucl Med 20(11):1063–9

25.

Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyzer F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J (2017) METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol 71(1):81–92. https://doi.org/10.1016/j.eururo.2016.05.033

Title: Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging
Authors: Edward William Johnston
Arash Latifoltojar
Harbir Singh Sidhu
Navin Ramachandran
Magdalena Sokolska
Alan Bainbridge
Caroline Moore
Hashim Uddin Ahmed
Shonit Punwani
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 6/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-018-5813-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging

Abstract

Objectives

Methods

Results

Conclusions

Key Points

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 6/2019

Role of one-pass breast lesion excision system in complete excision of high-risk breast lesions with atypia expressed as clusters of microcalcifications

Fractional flow reserve derived from CCTA may have a prognostic role in myocardial bridging

Intrauterine fetal MR versus postmortem MR imaging after therapeutic termination of pregnancy: evaluation of the concordance in the detection of brain abnormalities at early gestational stage

Changes in arterial oxygenation after portal decompression in Budd–Chiari syndrome patients with hepatopulmonary syndrome

Computed tomography improves the differentiation of infectious mediastinitis from normal postoperative changes after sternotomy in cardiac surgery

Introduction of an MR-based semi-quantitative score for assessing partial meniscectomy and relation to knee joint degenerative disease: data from the Osteoarthritis Initiative